Literature DB >> 15637370

Recent developments in gene transfer: risk and ethics.

Jonathan Kimmelman1.   

Abstract

Keywords:  Biomedical and Behavioral Research; Genetics and Reproduction

Mesh：

Year:  2005        PMID： 15637370      PMCID： PMC543871          DOI： 10.1136/bmj.330.7482.79

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  19 in total

1.  What makes clinical research ethical?

Authors:  E J Emanuel; D Wendler; C Grady
Journal:  JAMA       Date:  2000 May 24-31       Impact factor: 56.272

2.  Postmarketing surveillance and adverse drug reactions: current perspectives and future needs.

Authors:  T Brewer; G A Colditz
Journal:  JAMA       Date:  1999-03-03       Impact factor: 56.272

3.  Gene therapy. Viral vectors still pack surprises.

Authors:  E Marshall
Journal:  Science       Date:  2001-11-23       Impact factor: 47.728

4.  Starting clinical trials of xenotransplantation--reflections on the ethics of the early phase.

Authors:  S Welin
Journal:  J Med Ethics       Date:  2000-08       Impact factor: 2.903

5.  Gene therapy advisory committee: long-term monitoring of patients participating in gene therapy: Health Departments of the United Kingdom.

Authors:  Norman C Nevin; Jayne Spink
Journal:  Hum Gene Ther       Date:  2000-05-20       Impact factor: 5.695

Review 6.  Defining and describing benefit appropriately in clinical trials.

Authors:  N M King
Journal:  J Law Med Ethics       Date:  2000       Impact factor: 1.718

7.  Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.

Authors:  M A Kay; C S Manno; M V Ragni; P J Larson; L B Couto; A McClelland; B Glader; A J Chew; S J Tai; R W Herzog; V Arruda; F Johnson; C Scallan; E Skarsgard; A W Flake; K A High
Journal:  Nat Genet       Date:  2000-03       Impact factor: 38.330

8.  Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy.

Authors:  Salima Hacein-Bey-Abina; Françoise Le Deist; Frédérique Carlier; Cécile Bouneaud; Christophe Hue; Jean-Pierre De Villartay; Adrian J Thrasher; Nicolas Wulffraat; Ricardo Sorensen; Sophie Dupuis-Girod; Alain Fischer; E Graham Davies; Wietse Kuis; Lilly Leiva; Marina Cavazzana-Calvo
Journal:  N Engl J Med       Date:  2002-04-18       Impact factor: 91.245

9.  Points to consider for ethics committees in human gene therapy trials.

Authors:  U Dettweiler; P Simon
Journal:  Bioethics       Date:  2001-10       Impact factor: 1.898

10.  Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning.

Authors:  Alessandro Aiuti; Shimon Slavin; Memet Aker; Francesca Ficara; Sara Deola; Alessandra Mortellaro; Shoshana Morecki; Grazia Andolfi; Antonella Tabucchi; Filippo Carlucci; Enrico Marinello; Federica Cattaneo; Sergio Vai; Paolo Servida; Roberto Miniero; Maria Grazia Roncarolo; Claudio Bordignon
Journal:  Science       Date:  2002-06-28       Impact factor: 47.728
View more
  11 in total

1.  Risks of gene therapy should be weighed against lack of alternatives for many diseases.

Authors:  Robert E MacLaren; Robin R Ali; Adrian J Thrasher
Journal:  BMJ       Date:  2005-04-02

Review 2.  Targeting site-specific chromosome integration.

Authors:  Patricia Nuno-Gonzalez; Hsu Chao; Kazuhiro Oka
Journal:  Acta Biochim Pol       Date:  2005-06-03       Impact factor: 2.149

Review 3.  Gene therapy for children with cystic fibrosis--who has the right to choose?

Authors:  A Jaffé; S A Prasad; V Larcher; S Hart
Journal:  J Med Ethics       Date:  2006-06       Impact factor: 2.903

4.  Trust in early phase research: therapeutic optimism and protective pessimism.

Authors:  Scott Y H Kim; Robert G Holloway; Samuel Frank; Renee Wilson; Karl Kieburtz
Journal:  Med Health Care Philos       Date:  2008-07-16

5.  Stem cells and ethics: current issues.

Authors:  Jennifer Blair McCormick; Holly A Huso
Journal:  J Cardiovasc Transl Res       Date:  2009-12-01       Impact factor: 4.132

Review 6.  Accepting risk in clinical research: is the gene therapy field becoming too risk-averse?

Authors:  Claire T Deakin; Ian E Alexander; Ian Kerridge
Journal:  Mol Ther       Date:  2009-09-22       Impact factor: 11.454

7.  Nerve injection of viral vectors efficiently transfers transgenes into motor neurons and delivers RNAi therapy against ALS.

Authors:  Rui Wu; Hongyan Wang; Xugang Xia; Hongxia Zhou; Chunyan Liu; Maria Castro; Zuoshang Xu
Journal:  Antioxid Redox Signal       Date:  2009-07       Impact factor: 8.401

8.  Launching invasive, first-in-human trials against Parkinson's disease: ethical considerations.

Authors:  Jonathan Kimmelman; Alex John London; Bernard Ravina; Tim Ramsay; Mark Bernstein; Alan Fine; Frank W Stahnisch; Marina Elena Emborg
Journal:  Mov Disord       Date:  2009-10-15       Impact factor: 10.338

Review 9.  Molecular medicine: promises, promises?

Authors:  Michael Steel
Journal:  J R Soc Med       Date:  2005-05       Impact factor: 18.000

10.  Predicting synthetic rescues in metabolic networks.

Authors:  Adilson E Motter; Natali Gulbahce; Eivind Almaas; Albert-László Barabási
Journal:  Mol Syst Biol       Date:  2008-02-12       Impact factor: 11.429
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.